Trump Administration’s Proposal for a Permanent Medicare Drug Price Negotiation Framework
The Centers for Medicare and Medicaid Services (CMS) is circulating a proposal under the Trump administration to establish a permanent framework for Medicare drug price negotiations. This initiative aims to create a more transparent and sustainable process for reducing drug costs for millions of Medicare beneficiaries, while providing greater certainty for drug manufacturers.
According to a recent news release by CMS, the proposed guidelines would facilitate the negotiation and renegotiation of high-cost drugs from a single source, starting with the year of initial pricing in 2029. This price negotiation program was initially introduced as a part of the Inflation Reduction Act.
Administrator’s Statement on Proposed Rule
CMS Administrator Mehmet Oz, MD, emphasized the benefits of the proposal, stating, “This proposed rule lowers drug prices for seniors and provides continued savings. We are moving from annual updates to a permanent, predictable framework. This approach puts patients first, strengthens Medicare, and protects the innovation pipeline that delivers future cures.”
Expansion of Negotiable Drugs
Under this framework, CMS plans to select up to 20 additional negotiable drugs covered under Medicare Part D and/or payable under Part B for a fourth negotiation cycle in 2029 and future cycles. By law, the negotiation program is required to transition from implementation through guidance to codification into regulations as a permanent, long-term framework, according to CMS.
Addressing Program Integrity and Biotech Drugs
The proposal also suggests a narrow modification to the single-source identification policy for qualified drug products. This change aims to address potential program integrity concerns posed by certain new formulations.
Additionally, CMS proposes to implement the statutory interim floor for small biotech drugs. This measure will prevent CMS from offering or agreeing to a counteroffer for a maximum fair price (MFP) for small biotech drugs below the established floor for certain eligible drugs during the initial price applicability years of 2029 and 2030.
Impact on Medicare Part D and the Inflation Reduction Act
The proposed rule would also codify two policies impacting Medicare Part D performance, one concerning the inclusion of selected drugs in the formulary and the definition of the “negotiated price.” These measures are part of the broader Inflation Reduction Act, which introduced drug price negotiations under the Biden administration.
CMS has already negotiated prices for 25 high-cost drugs in the program’s first two years, claiming significant savings for Medicare and its beneficiaries. The first IRA-backed Medicare price cuts took effect earlier this year.
Industry Reaction and Future Implications
Despite the pharmaceutical industry’s public campaign against IRA price negotiations, criticizing them as akin to government price controls, the industry has not been able to effectively challenge these measures. CMS’s efforts are praised for delivering real savings, as noted by Chris Klomp, director of Medicare and chief adviser to the U.S. Department of Health and Human Services. “This rule builds on that foundation by establishing clear, consistent rules of the road – giving patients, health plans, pharmacies, and drug manufacturers the certainty they need while we continue to drive down costs,” Klomp stated.
For further details on this evolving topic, you can read more Here.
“`
